
Ferring names Aaron Graff CEO of US holding company
pharmafile | March 2, 2016 | Appointment | Medical Communications |
Swiss fertility treatment company Ferring Pharmaceuticals on Tuesday named Aaron Graff the chief executive of its US unit, Ferring Holding.
In this role, Graff assumes direct responsibility for all Ferring US activities, including commercial operations, clinical development, and manufacturing.
Graff will report to the board of directors of Ferring Holding Company, chaired by Michel Pettigrew, president of the executive board and chief operating officer, Ferring Group.
Commenting on his appointment, Graff says: “A US-based CEO helps ensure that important decisions concerning the US business benefit from the insight that only close proximity to the market provides.”
Graff joined Ferring Pharmaceuticals as president and chief operating officer in 2010, and has overseen consistent double-digit annual growth in the US subsidiary and the expansion of its US presence to include an integrated operations center.
Prior to joining Ferring, he worked for over 17 years at Bristol-Myers Squibb in both the US and Europe.






